Monitor Longevity Health Holdings' capital-raising activity and Elevai Skincare net sales for prepayment triggers and royalty growth. The agreement provides PMGC with predictable near-term cash flow but the total value depends on product line performance.
Price Chart
Executive Summary
PMGC Holdings Inc. (ELAB) announced a binding payment agreement with Longevity Health Holdings to convert the 5% net sales royalty from the January 2025 Elevai Skincare sale into scheduled monthly cash payments through August 2031. The agreement secures a $94,937 acknowledged 2025 royalty obligation with interest, plus $10,000/month installments and mandatory prepayments from Longevity capital events, creating a non-dilutive, recurring cash flow stream for PMGC.
Key Facts
- PMGC and its subsidiary NorthStrive Biosciences entered a payment agreement with Longevity Health Holdings covering the 5% net sales royalty from the Elevai Skincare divestiture.
- Longevity acknowledged a $94,937 2025 royalty obligation with interest at WSJ Prime Rate + 1.00% from April 2026 due date.
- Structured monthly payments of $10,000 begin October 15, 2026, with all amounts due by August 28, 2031.
- Mandatory prepayments of 15% of net cash proceeds from Longevity capital raises exceeding $350,000, asset sales, and settlements.
- The agreement converts a contingent royalty into contractual, interest-bearing cash flow that is non-dilutive to PMGC shareholders.
Financial Impact
Secures $94,937 in acknowledged 2025 royalty plus $10,000/month through August 2031, with interest and mandatory prepayment provisions. Total future cash flows depend on Elevai Skincare net sales performance.
Risk Factors
- Longevity Health Holdings may fail to make payments or become insolvent, triggering acceleration and enforcement rights.
- The royalty stream depends on Elevai Skincare net sales, which could decline and reduce future payments.
- The $10,000/month base payment is modest relative to PMGC's overall capital needs.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-101143 |
| Document: ea030585501ex99-1.htm | 0001213900-26-101143 |
| Document: 0001213900-26-101143-index-headers.html | 0001213900-26-101143 |
| Document: 0001213900-26-101143-index.html | 0001213900-26-101143 |
| Document: 0001213900-26-101143.txt | 0001213900-26-101143 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 29, 2026 27d ago | Press Release | $3.67 $3.54 | ▼ −3.54% | ▼ −3.34% | $2.61 (−28.88%) |
Sep 18, 2026 5w ago | 8-K | $4.78 $4.42 | ▼ −7.53% | ▼ −9.08% | $2.61 (−45.40%) |
Sep 18, 2026 5w ago | Press Release | $4.78 $4.42 | ▼ −7.53% | ▼ −9.08% | $2.61 (−45.40%) |
Aug 19, 2026 9w ago | Press Release | $0.5603 $0.6100 | ▲ +8.87% | ▲ +9.71% | $2.61 (+365.82%) |
Aug 14, 2026 10w ago | Press Release | $0.9100 $0.8730 | ▼ −4.07% | ▼ −3.59% | $2.61 (+186.81%) |
Jul 29, 2026 12w ago | Press Release | $0.8800 $0.9493 | ▲ +7.88% | ▲ +6.20% | $2.61 (+196.59%) |
Jul 9, 2026 15w ago | 8-K | $1.12 $1.09 | ▼ −2.68% | ▼ −1.91% | $2.61 (+133.04%) |
Jul 1, 2026 16w ago | 8-K | $1.28 $1.18 | ▼ −7.81% | ▼ −7.68% | $2.61 (+103.91%) |
Jun 8, 2026 20w ago | Press Release | $1.59 $1.41 | ▼ −11.32% | ▼ −11.03% | $2.61 (+64.15%) |
Jun 5, 2026 20w ago | 8-K | $1.59 $1.41 | ▼ −11.32% | ▼ −11.03% | $2.61 (+64.15%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers